ESMO 2019 | The value of PD-L1 as a biomarker beyond lung cancers

Kevin Harrington

Kevin Harrington, PhD, MBBS, Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, London, UK, explains to us the value of PD-L1 as a biomarker, focusing on head and neck squamous cell carcinoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video